Floatz logo

ROPEGINTERFERON ALFA-2B

Azacitidine

M.D. Anderson Cancer Centerprotein_peptidePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Azacitidine cohort.

Asset / SponsorPhaseRating
Azacitidine
M.D. Anderson Cancer Center
Phase 1/2CC
Venetoclax
Henan Cancer Hospital
N/AD
INTERFERON ALPHA 1B
Henan Cancer Hospital
N/AD
Thalidomide
Henan Cancer Hospital
N/AD

Same molecule, other indications

ROPEGINTERFERON ALFA-2B is also rated in:

Alfa-2bDormant
CCC
Indicative ·
48 / 100
View asset →
MDS/AMLDormant
CC
Indicative ·
47 / 100
View asset →
primary cutaneous T-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →